All In Biotech

Drug Trial Radar · NCT07571746

A Study to Assess the Effect of Surovatamig in Adult Participants With Antibody-mediated Kidney Disease

A Phase 2, Open-label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of Surovatamig in Adults With Antibody-mediated Kidney Disease

Last checked: Nov 20, 2026Latest source record: Oct 20, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

43

Planned (sponsor's estimate)

Start

Mar 28, 2026

Primary completion

Oct 13, 2028

Study completion Apr 15, 2030

Sponsor

Lead sponsor
AstraZenecaAstraZeneca (AZN)
Sponsor type
Industry
First posted
May 6, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Not applicable (single group)
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to assess the safety, tolerability, pharmacokinetic, and efficacy of surovatamig administered by subcutaneous injection in adult participants with primary membranous nephropathy.

Conditions

  • Primary Membranous Nephropathy

Interventions

  • SurovatamigDrug

    Participants will receive Surovatamig subcutaneously

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of participants with adverse events.Time frame: Through study completion, an average of 2 years
  2. Change from baseline in UPCR (from 24-hour urine collection or the intended 24-hour urine collection)Time frame: At 6 months

Locations

27 sites in 9 countries. Site status is shown where the registry gives one.

  • Research Site

    Los Angeles, California · Withdrawn

  • Research Site

    Los Angeles, California · Not yet recruiting

  • Research Site

    Iowa City, Iowa · Not yet recruiting

  • Research Site

    Bethesda, Maryland · Not yet recruiting

  • Research Site

    New York, New York · Not yet recruiting

  • Research Site

    Houston, Texas · Recruiting

  • Research Site

    Houston, Texas · Not yet recruiting

  • Research Site

    Ieper, Belgium · Not yet recruiting

  • Research Site

    Beijing, China · Not yet recruiting

  • Research Site

    Beijing, China · Not yet recruiting

  • Research Site

    Bordeaux, France · Not yet recruiting

  • Research Site

    Créteil, France · Withdrawn

  • Research Site

    Lyon, France · Not yet recruiting

  • Research Site

    Nantes, France · Not yet recruiting

  • Research Site

    Nîmes, France · Not yet recruiting

  • Research Site

    Düsseldorf, Germany · Not yet recruiting

  • Research Site

    Hanover, Germany · Not yet recruiting

  • Research Site

    München, Germany · Not yet recruiting

  • Research Site

    Brescia, Italy · Not yet recruiting

  • Research Site

    Rozzano, Italy · Not yet recruiting

  • Research Site

    Torino, Italy · Not yet recruiting

  • Research Site

    Verona, Italy · Withdrawn

  • Research Site

    Lodz, Poland · Not yet recruiting

  • Research Site

    Barcelona, Spain · Not yet recruiting

  • Research Site

    Madrid, Spain · Not yet recruiting

  • Research Site

    London, United Kingdom · Not yet recruiting

  • Research Site

    Manchester, United Kingdom · Not yet recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.